1
|
Mori F, Pascali G, Berra S, Lazzarotti A, Panetta D, Rocchiccioli S, Ceccherini E, Norelli F, Morlando A, Donadelli R, Clivio A, Farina C, Noris M, Salvadori PA, Remuzzi G. Proof of concept of a new plasma complement Factor H from waste plasma fraction. Front Immunol 2024; 15:1334151. [PMID: 38919628 PMCID: PMC11197005 DOI: 10.3389/fimmu.2024.1334151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 05/24/2024] [Indexed: 06/27/2024] Open
Abstract
Introduction Complement factor H (FH) is a major regulator of the complement alternative pathway, its mutations predispose to an uncontrolled activation in the kidney and on blood cells and to secondary C3 deficiency. Plasma exchange has been used to correct for FH deficiency and although the therapeutic potential of purified FH has been suggested by in vivo experiments in animal models, a clinical approved FH concentrate is not yet available. We aimed to develop a purification process of FH from a waste fraction rather than whole plasma allowing a more efficient and ethical use of blood and plasma donations. Methods Waste fractions from industrial plasma fractionation (pooled human plasma) were analyzed for FH content by ELISA. FH was purified from unused fraction III and its decay acceleration, cofactor, and C3 binding capacity were characterized in vitro. Biodistribution was assessed by high-resolution dynamic PET imaging. Finally, the efficacy of the purified FH preparation was tested in the mouse model of C3 glomerulopathy (Cfh-/- mice). Results Our purification method resulted in a high yield of highly purified (92,07%), pathogen-safe FH. FH concentrate is intact and fully functional as demonstrated by in vitro functional assays. The biodistribution revealed lower renal and liver clearance of human FH in Cfh-/- mice than in wt mice. Treatment of Cfh-/- mice documented its efficacy in limiting C3 activation and promoting the clearance of C3 glomerular deposits. Conclusion We developed an efficient and economical system for purifying intact and functional FH, starting from waste material of industrial plasma fractionation. The FH concentrate could therefore constitute possible treatments options of patients with C3 glomerulopathy, particularly for those with FH deficiency, but also for patients with other diseases associated with alternative pathway activation.
Collapse
Affiliation(s)
- Filippo Mori
- Research and Innovation, Kedrion Biopharma, Lucca, Italy
| | - Giancarlo Pascali
- Biosciences, Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW, Australia
- School of Chemistry, University of New South Wales, Kensington, NSW, Australia
| | - Silvia Berra
- Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy
| | | | - Daniele Panetta
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Silvia Rocchiccioli
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Elisa Ceccherini
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Francesco Norelli
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Antonio Morlando
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Roberta Donadelli
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - Alberto Clivio
- Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy
| | - Claudio Farina
- Research and Innovation, Kedrion Biopharma, Lucca, Italy
| | - Marina Noris
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - Piero A. Salvadori
- Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italy
| | - Giuseppe Remuzzi
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| |
Collapse
|
2
|
Poonoosamy J, Kaspor A, Schreinemachers C, Bosbach D, Cheong O, Kowalski PM, Obaied A. A radiochemical lab-on-a-chip paired with computer vision to unlock the crystallization kinetics of (Ba,Ra)SO 4. Sci Rep 2024; 14:9502. [PMID: 38664523 PMCID: PMC11045812 DOI: 10.1038/s41598-024-59888-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
(Ra,Ba)SO4 solid solutions are commonly encountered as problematic scales in subsurface energy-related applications, e.g., geothermal systems, hydraulic fracturing, conventional oil and gas, etc. Despite its relevance, its crystallization kinetics were never determined because of radium (226), high radioactivity (3.7 × 1010 Bq g-1), and utilization in contemporary research, therefore constrained to trace amounts (< 10-8 M) with the composition of BaxRa1-xSO4 commonly restricted to x > 0.99. What if lab-on-a-chip technology could create new opportunities, enabling the study of highly radioactive radium beyond traces to access new information? In this work, we developed a lab-on-a-chip experiment paired with computer vision to evaluate the crystal growth rate of (Ba,Ra)SO4 solid solutions. The computer vision algorithm enhances experimental throughput, yielding robust statistical insights and further advancing the efficiency of such experiments. The 3D analysis results of the precipitated crystals using confocal Raman spectroscopy suggested that {210} faces grew twice as fast as {001} faces, mirroring a common observation reported for pure barite. The crystal growth rate of (Ba0.5Ra0.5)SO4 follows a second-order reaction with a kinetic constant equal to (1.23 ± 0.09) × 10-10 mol m-2 s-1.
Collapse
Affiliation(s)
- Jenna Poonoosamy
- Institute of Energy and Climate Research, Forschungszentrum Jülich GmbH, IEK-6): Nuclear Waste Management, 52425, Jülich, Germany.
| | - Alexander Kaspor
- Institute of Energy and Climate Research, Forschungszentrum Jülich GmbH, IEK-6): Nuclear Waste Management, 52425, Jülich, Germany
| | - Christian Schreinemachers
- Institute of Energy and Climate Research, Forschungszentrum Jülich GmbH, IEK-6): Nuclear Waste Management, 52425, Jülich, Germany
| | - Dirk Bosbach
- Institute of Energy and Climate Research, Forschungszentrum Jülich GmbH, IEK-6): Nuclear Waste Management, 52425, Jülich, Germany
| | - Oskar Cheong
- Institute of Energy and Climate Research (IEK-13): Theory and Computation of Energy Materials, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA Energy and Center for Simulation and Data Science (CSD), 52425, Jülich, Germany
- Chair of Theory and Computation of Energy Materials, Faculty of Georesources and Materials Engineering, RWTH Aachen University, Intzestrasse 5, 52072, Aachen, Germany
| | - Piotr M Kowalski
- Institute of Energy and Climate Research (IEK-13): Theory and Computation of Energy Materials, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA Energy and Center for Simulation and Data Science (CSD), 52425, Jülich, Germany
| | - Abdulmonem Obaied
- Institute of Energy and Climate Research, Forschungszentrum Jülich GmbH, IEK-6): Nuclear Waste Management, 52425, Jülich, Germany
| |
Collapse
|
3
|
Fonseca ICF, Pais ML, Rodrigues FMS, Sereno J, Castelo-Branco M, Cavadas C, Pereira MM, Abrunhosa AJ. Improved Chemical and Radiochemical Synthesis of Neuropeptide Y Y 2 Receptor Antagonist N-Methyl-JNJ-31020028 and Preclinical Positron Emission Tomography Studies. Pharmaceuticals (Basel) 2024; 17:474. [PMID: 38675435 PMCID: PMC11053772 DOI: 10.3390/ph17040474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2024] [Revised: 03/30/2024] [Accepted: 04/03/2024] [Indexed: 04/28/2024] Open
Abstract
Neuropeptide Y (NPY) is one of the most abundant peptides in the central nervous system of mammals and is involved in several physiological processes through NPY Y1, Y2, Y4 and Y5 receptors. Of those, the Y2 receptor has particular relevance for its autoreceptor role in inhibiting the release of NPY and other neurotransmitters and for its involvement in relevant mechanisms such as feeding behaviour, cognitive processes, emotion regulation, circadian rhythms and disorders such as epilepsy and cancer. PET imaging of the Y2 receptor can provide a valuable platform to understand this receptor's functional role and evaluate its potential as a therapeutic target. In this work, we set out to refine the chemical and radiochemical synthesis of the Y2 receptor antagonist N-[11C]Me-JNJ31020028 for in vivo PET imaging studies. The non-radioactive reference compound, N-Me-JNJ-31020028, was synthesised through batch synthesis and continuous flow methodology, with 43% and 92% yields, respectively. N-[11C]Me-JNJ-31020028 was obtained with a radiochemical purity > 99%, RCY of 31% and molar activity of 156 GBq/μmol. PET imaging clearly showed the tracer's biodistribution in several areas of the mouse brain and gut where Y2 receptors are known to be expressed.
Collapse
Affiliation(s)
- Inês C. F. Fonseca
- CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, 3000-548 Coimbra, Portugal; (I.C.F.F.); (M.L.P.); (J.S.); (M.C.-B.)
- Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal;
- ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Mariana Lapo Pais
- CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, 3000-548 Coimbra, Portugal; (I.C.F.F.); (M.L.P.); (J.S.); (M.C.-B.)
| | - Fábio M. S. Rodrigues
- Coimbra Chemistry Centre, University of Coimbra, 3000-548 Coimbra, Portugal; (F.M.S.R.); (M.M.P.)
| | - José Sereno
- CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, 3000-548 Coimbra, Portugal; (I.C.F.F.); (M.L.P.); (J.S.); (M.C.-B.)
- ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Miguel Castelo-Branco
- CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, 3000-548 Coimbra, Portugal; (I.C.F.F.); (M.L.P.); (J.S.); (M.C.-B.)
- ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal
- Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Cláudia Cavadas
- Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal;
- CNC—Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal
- CIBB—Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, 3004-531 Coimbra, Portugal
| | - Mariette M. Pereira
- Coimbra Chemistry Centre, University of Coimbra, 3000-548 Coimbra, Portugal; (F.M.S.R.); (M.M.P.)
| | - Antero J. Abrunhosa
- CIBIT/ICNAS, Institute for Nuclear Sciences Applied to Health, University of Coimbra, 3000-548 Coimbra, Portugal; (I.C.F.F.); (M.L.P.); (J.S.); (M.C.-B.)
- ICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal
| |
Collapse
|
4
|
Mc Veigh M, Bellan LM. Microfluidic synthesis of radiotracers: recent developments and commercialization prospects. LAB ON A CHIP 2024; 24:1226-1243. [PMID: 38165824 DOI: 10.1039/d3lc00779k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2024]
Abstract
Positron emission tomography (PET) is a powerful diagnostic tool that holds incredible potential for clinicians to track a wide variety of biological processes using specialized radiotracers. Currently, however, a single radiotracer accounts for over 95% of procedures, largely due to the cost of radiotracer synthesis. Microfluidic platforms provide a solution to this problem by enabling a dose-on-demand pipeline in which a single benchtop platform would synthesize a wide array of radiotracers. In this review, we will explore the field of microfluidic production of radiotracers from early research to current development. Furthermore, the benefits and drawbacks of different microfluidic reactor designs will be analyzed. Lastly, we will discuss the various engineering considerations that must be addressed to create a fully developed, commercially effective platform that can usher the field from research and development to commercialization.
Collapse
Affiliation(s)
- Mark Mc Veigh
- Interdisciplinary Materials Science Program, Vanderbilt University, Nashville, TN, 37235, USA
| | - Leon M Bellan
- Department of Mechanical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA
| |
Collapse
|
5
|
Mallapura H, Ovdiichuk O, Jussing E, Thuy TA, Piatkowski C, Tanguy L, Collet-Defossez C, Långström B, Halldin C, Nag S. Microfluidic-based production of [ 68Ga]Ga-FAPI-46 and [ 68Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer. EJNMMI Radiopharm Chem 2023; 8:42. [PMID: 38091157 PMCID: PMC10719436 DOI: 10.1186/s41181-023-00229-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Accepted: 12/01/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These tracers have exhibited promising results in theranostic applications, fueling interest in exploring them for clinical use. Among these probes, 68Ga-labeled FAPI-46 and DOTA-TOC have emerged as key players due to their ability to diagnose a broad spectrum of cancers ([68Ga]Ga-FAPI-46) in late-phase studies, whereas [68Ga]Ga-DOTA-TOC is clinically approved for neuroendocrine tumors. To facilitate their production, we leveraged a microfluidic cassette-based iMiDEV radiosynthesizer, enabling the synthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC based on a dose-on-demand (DOD) approach. RESULTS Different mixing techniques were explored to influence radiochemical yield. We achieved decay-corrected yield of 44 ± 5% for [68Ga]Ga-FAPI-46 and 46 ± 7% for [68Ga]Ga-DOTA-TOC in approximately 30 min. The radiochemical purities (HPLC) of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC were 98.2 ± 0.2% and 98.4 ± 0.9%, respectively. All the quality control results complied with European Pharmacopoeia quality standards. We optimized various parameters, including 68Ga trapping and elution, cassette batches, passive mixing in the reactor, and solid-phase extraction (SPE) purification and formulation. The developed synthesis method reduced the amount of precursor and other chemicals required for synthesis compared to conventional radiosynthesizers. CONCLUSIONS The microfluidic-based approach enabled the implementation of radiosynthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC on the iMiDEV™ microfluidic module, paving the way for their use in preclinical and clinical applications. The microfluidic synthesis approach utilized 2-3 times less precursor than cassette-based conventional synthesis. The synthesis method was also successfully validated in a similar microfluidic iMiDEV module at a different research center for the synthesis of [68Ga]Ga-FAPI-46 with limited runs. Our study demonstrated the potential of microfluidic methods for efficient and reliable radiometal-based radiopharmaceutical synthesis, contributing valuable insights for future advancements in this field and paving the way for routine clinical applications in the near future.
Collapse
Affiliation(s)
- Hemantha Mallapura
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176, Stockholm, Sweden.
| | - Olga Ovdiichuk
- Nancyclotep, Molecular Imaging Platform, 5 Rue du Morvan, 54500, Vandoeuvre Les Nancy, France
| | - Emma Jussing
- Department of Oncology and Pathology, Karolinska Institutet, 17177, Stockholm, Sweden
- Department of Radiopharmacy, Karolinska University Hospital, 17176, Stockholm, Sweden
| | - Tran A Thuy
- Department of Oncology and Pathology, Karolinska Institutet, 17177, Stockholm, Sweden
- Department of Radiopharmacy, Karolinska University Hospital, 17176, Stockholm, Sweden
| | | | - Laurent Tanguy
- PMB-Alcen, Route des Michels CD56, 13790, Peynier, France
| | - Charlotte Collet-Defossez
- Nancyclotep, Molecular Imaging Platform, 5 Rue du Morvan, 54500, Vandoeuvre Les Nancy, France
- Inserm, IADI, Université de Lorraine, 54000, Nancy, France
| | - Bengt Långström
- Department of Chemistry, Uppsala University, 75123, Uppsala, Sweden
| | - Christer Halldin
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176, Stockholm, Sweden
| | - Sangram Nag
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-17176, Stockholm, Sweden
| |
Collapse
|
6
|
Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery. Mol Imaging Biol 2023; 25:991-1019. [PMID: 37845582 DOI: 10.1007/s11307-023-01857-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 09/03/2023] [Accepted: 09/05/2023] [Indexed: 10/18/2023]
Abstract
Critical advances in radionuclide therapy have led to encouraging new options for cancer treatment through the pairing of clinically useful radiation-emitting radionuclides and innovative pharmaceutical discovery. Of the various subatomic particles used in therapeutic radiopharmaceuticals, alpha (α) particles show great promise owing to their relatively large size, delivered energy, finite pathlength, and resulting ionization density. This review discusses the therapeutic benefits of α-emitting radiopharmaceuticals and their pairing with appropriate diagnostics, resulting in innovative "theranostic" platforms. Herein, the current landscape of α particle-emitting radionuclides is described with an emphasis on their use in theranostic development for cancer treatment. Commonly studied radionuclides are introduced and recent efforts towards their production for research and clinical use are described. The growing popularity of these radionuclides is explained through summarizing the biological effects of α radiation on cancer cells, which include DNA damage, activation of discrete cell death programs, and downstream immune responses. Examples of efficient α-theranostic design are described with an emphasis on strategies that lead to cellular internalization and the targeting of proteins involved in therapeutic resistance. Historical barriers to the clinical deployment of α-theranostic radiopharmaceuticals are also discussed. Recent progress towards addressing these challenges is presented along with examples of incorporating α-particle therapy in pharmaceutical platforms that can be easily converted into diagnostic counterparts.
Collapse
Affiliation(s)
- Ryan P Coll
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Rd, Houston, TX, 77054, USA
| | - Scott J Bright
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Blvd, Houston, TX, 77030, USA
| | - David K J Martinus
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Blvd, Houston, TX, 77030, USA
| | - Dimitra K Georgiou
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Rd, Houston, TX, 77054, USA
| | - Gabriel O Sawakuchi
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Blvd, Houston, TX, 77030, USA
| | - H Charles Manning
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1881 East Rd, Houston, TX, 77054, USA.
- Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, 1881 East Rd, Houston, TX, 77054, USA.
| |
Collapse
|
7
|
Lu Y, He Y, Schibli R, Mu L, van Dam RM. Proof-of-concept optimization of a copper-mediated 18F-radiosynthesis of a novel MAGL PET tracer on a high-throughput microdroplet platform and its macroscale translation. LAB ON A CHIP 2023; 23:4652-4663. [PMID: 37818614 PMCID: PMC10608794 DOI: 10.1039/d3lc00735a] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/12/2023]
Abstract
Copper-mediated radiofluorination has demonstrated remarkable potential in forming aromatic C-18F bonds of radioligands for positron emission tomography (PET). Achieving optimal results often requires optimization efforts, requiring a substantial amount of radiolabeling precursor and time, severely limiting the experimental throughput. Recently, we successfully showcased the feasibility of performing and optimizing Cu-mediated radiosynthesis on a high-throughput microdroplet platform using the well-known and clinically used radioligand [18F]FDOPA as an illustrative example. In our current work, we optimized the Cu-mediated synthesis of a novel monoacylglycerol lipase (MAGL) PET tracer ([18F]YH149), showing the versatility of droplet-based techniques for early stage tracer development. Across 5 days, we conducted a total of 117 experiments, studying 36 distinct conditions, while utilizing <15 mg of total organoboron precursor. Compared to the original report in which the radiochemical yield (RCY) was 4.4 ± 0.5% (n = 5), the optimized droplet condition provided a substantial improvement in RCY (52 ± 8%, n = 4) and showed excellent radiochemical purity (100%) and molar activity (77-854 GBq μmol-1), using a starting activity of 0.2-1.45 GBq. Furthermore, we showed for the first time a translation of the optimized microscale conditions to a vial-based method. With similar starting activity (0.2-1.44 GBq), the translated synthesis exhibited a comparable RCY of 50 ± 10% (n = 4) while maintaining excellent radiochemical purity (100%) and acceptable molar activity (20-46 GBq μmol-1). The successful translation to vial-based reactions ensures wider applicability of the optimized synthesis by leveraging widely available commercial vial-based synthesis modules.
Collapse
Affiliation(s)
- Yingqing Lu
- Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
| | - Yingfang He
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Roger Schibli
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Linjing Mu
- Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - R Michael van Dam
- Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
| |
Collapse
|
8
|
Elkawad H, Xu Y, Tian M, Jin C, Zhang H, Yu K, He Q. Recent advances in microfluidic devices for radiosynthesis of PET‐imaging probes. Chem Asian J 2022; 17:e202200579. [PMID: 35909081 DOI: 10.1002/asia.202200579] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 07/29/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Husamelden Elkawad
- The second affiliated hospital of Zhejiang University Nuclear Medicine and PET center CHINA
| | - Yangyang Xu
- Zhejiang University b. College of Chemical & Biological Engineering CHINA
| | - Mei Tian
- The second affiliated hospital of Zhejiang University Nuclear Medicine & PET center CHINA
| | - Chenyang Jin
- Zhejiang University b. College of Chemical & Biological Engineering CHINA
| | - Hong Zhang
- The second affiliated hospital of Zhejiang University b. College of Chemical & Biological Engineering CHINA
| | - Kaiwu Yu
- Zhejiang University b. College of Chemical & Biological Engineering CHINA
| | - Qinggang He
- Zhejiang University Chemical Engineering 38 Zheda Rd. 310027 Hangzhou CHINA
| |
Collapse
|
9
|
Microliter-scale reaction arrays for economical high-throughput experimentation in radiochemistry. Sci Rep 2022; 12:10263. [PMID: 35715457 PMCID: PMC9205965 DOI: 10.1038/s41598-022-14022-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 05/31/2022] [Indexed: 01/14/2023] Open
Abstract
The increasing number of positron-emission tomography (PET) tracers being developed to aid drug development and create new diagnostics has led to an increased need for radiosynthesis development and optimization. Current radiosynthesis instruments are designed to produce large-scale clinical batches and are often limited to performing a single synthesis before they must be decontaminated by waiting for radionuclide decay, followed by thorough cleaning or disposal of synthesizer components. Though with some radiosynthesizers it is possible to perform a few sequential radiosyntheses in a day, none allow for parallel radiosyntheses. Throughput of one or a few experiments per day is not well suited for rapid optimization experiments. To combat these limitations, we leverage the advantages of droplet-radiochemistry to create a new platform for high-throughput experimentation in radiochemistry. This system contains an array of 4 heaters, each used to heat a set of 16 reactions on a small chip, enabling 64 parallel reactions for the rapid optimization of conditions in any stage of a multi-step radiosynthesis process. As examples, we study the syntheses of several 18F-labeled radiopharmaceuticals ([18F]Flumazenil, [18F]PBR06, [18F]Fallypride, and [18F]FEPPA), performing > 800 experiments to explore the influence of parameters including base type, base amount, precursor amount, solvent, reaction temperature, and reaction time. The experiments were carried out within only 15 experiment days, and the small volume (~ 10 μL compared to the ~ 1 mL scale of conventional instruments) consumed ~ 100 × less precursor per datapoint. This new method paves the way for more comprehensive optimization studies in radiochemistry and substantially shortening PET tracer development timelines.
Collapse
|
10
|
Chermat R, Ziaee M, Mak DY, Refet-Mollof E, Rodier F, Wong P, Carrier JF, Kamio Y, Gervais T. Radiotherapy on-chip: microfluidics for translational radiation oncology. LAB ON A CHIP 2022; 22:2065-2079. [PMID: 35477748 DOI: 10.1039/d2lc00177b] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The clinical importance of radiotherapy in the treatment of cancer patients justifies the development and use of research tools at the fundamental, pre-clinical, and ultimately clinical levels, to investigate their toxicities and synergies with systemic agents on relevant biological samples. Although microfluidics has prompted a paradigm shift in drug discovery in the past two decades, it appears to have yet to translate to radiotherapy research. However, the materials, dimensions, design versatility and multiplexing capabilities of microfluidic devices make them well-suited to a variety of studies involving radiation physics, radiobiology and radiotherapy. This review will present the state-of-the-art applications of microfluidics in these fields and specifically highlight the perspectives offered by radiotherapy on-a-chip in the field of translational radiobiology and precision medicine. This body of knowledge can serve both the microfluidics and radiotherapy communities by identifying potential collaboration avenues to improve patient care.
Collapse
Affiliation(s)
- Rodin Chermat
- μFO Lab, Polytechnique Montréal, Montréal, QC, Canada.
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
| | - Maryam Ziaee
- μFO Lab, Polytechnique Montréal, Montréal, QC, Canada.
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
| | - David Y Mak
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
| | - Elena Refet-Mollof
- μFO Lab, Polytechnique Montréal, Montréal, QC, Canada.
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
| | - Francis Rodier
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
- Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montreal, QC, Canada
| | - Philip Wong
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
- Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
| | - Jean-François Carrier
- Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montreal, QC, Canada
- Département de Physique, Université de Montréal, Montréal, QC, Canada
- Département de Radio-oncologie, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - Yuji Kamio
- Département de Radio-oncologie, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
- Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada
| | - Thomas Gervais
- μFO Lab, Polytechnique Montréal, Montréal, QC, Canada.
- Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
| |
Collapse
|
11
|
Boschi S, Todde S. PET radiopharmacy and automation. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00004-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Hansen SB, Bender D. Advancement in production of radiotracers. Semin Nucl Med 2021; 52:266-275. [PMID: 34836618 DOI: 10.1053/j.semnuclmed.2021.10.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 10/19/2021] [Indexed: 11/11/2022]
Abstract
After introduction of the first commercial combined PET and/or CT technology in 2001, this diagnostic tool quickly became a clinical success and was considered the fastest growing diagnostic imaging technology ever. However, this technique is very dependent on the availability of positron emitting isotopes and radiochemistry to incorporate the radioactive isotopes into larger molecules of physiological interest. Within this review article a historical overview starting with the first applications of positron emitting isotopes in the 1930's is presented. Afterwards a more detailed presentation summarizing the physical basis and advancements in cyclotron technology is given. Radiochemical and/or pharmaceutical advancements are presented systematically for the most significant isotopes like 15O, 13N, 11C, 18F and 68Ga Besides these major PET isotopes, advancements of other radio-metals and future perspectives regarding application of new radionuclides will be discussed. Finally, very interesting new and compact accelerator technology and microfluidic chemical reaction approaches will be discussed. Especially, new compact accelerator technology might be new quantum leap within this radiodiagnostic technology and might result in even further prevalence, ultimately envisioned by the dose-on-demand concept that will be briefly discussed.
Collapse
Affiliation(s)
- Søren Baarsgaard Hansen
- Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
| | - Dirk Bender
- Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|
13
|
Lisova K, Wang J, Hajagos TJ, Lu Y, Hsiao A, Elizarov A, van Dam RM. Economical droplet-based microfluidic production of [ 18F]FET and [ 18F]Florbetaben suitable for human use. Sci Rep 2021; 11:20636. [PMID: 34667246 PMCID: PMC8526601 DOI: 10.1038/s41598-021-99111-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 08/26/2021] [Indexed: 01/22/2023] Open
Abstract
Current equipment and methods for preparation of radiopharmaceuticals for positron emission tomography (PET) are expensive and best suited for large-scale multi-doses batches. Microfluidic radiosynthesizers have been shown to provide an economic approach to synthesize these compounds in smaller quantities, but can also be scaled to clinically-relevant levels. Batch microfluidic approaches, in particular, offer significant reduction in system size and reagent consumption. Here we show a simple and rapid technique to concentrate the radioisotope, prior to synthesis in a droplet-based radiosynthesizer, enabling production of clinically-relevant batches of [18F]FET and [18F]FBB. The synthesis was carried out with an automated synthesizer platform based on a disposable Teflon-silicon surface-tension trap chip. Up to 0.1 mL (4 GBq) of radioactivity was used per synthesis by drying cyclotron-produced aqueous [18F]fluoride in small increments directly inside the reaction site. Precursor solution (10 µL) was added to the dried [18F]fluoride, the reaction chip was heated for 5 min to perform radiofluorination, and then a deprotection step was performed with addition of acid solution and heating. The product was recovered in 80 µL volume and transferred to analytical HPLC for purification. Purified product was formulated via evaporation and resuspension or a micro-SPE formulation system. Quality control testing was performed on 3 sequential batches of each tracer. The method afforded production of up to 0.8 GBq of [18F]FET and [18F]FBB. Each production was completed within an hour. All batches passed quality control testing, confirming suitability for human use. In summary, we present a simple and efficient synthesis of clinically-relevant batches of [18F]FET and [18F]FBB using a microfluidic radiosynthesizer. This work demonstrates that the droplet-based micro-radiosynthesizer has a potential for batch-on-demand synthesis of 18F-labeled radiopharmaceuticals for human use.
Collapse
Affiliation(s)
- Ksenia Lisova
- Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California Los Angeles, Los Angeles, CA, USA
| | - Jia Wang
- Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA
- Bioengineering Department, University of California Los Angeles, Los Angeles, CA, USA
| | | | - Yingqing Lu
- Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California Los Angeles, Los Angeles, CA, USA
| | | | | | - R Michael van Dam
- Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California Los Angeles, Los Angeles, CA, USA.
- Bioengineering Department, University of California Los Angeles, Los Angeles, CA, USA.
| |
Collapse
|
14
|
Ma L, Cui Y, Sheng L, Du C, Deng J, Luo G. Determination of interfacial tension and viscosity under dripping flow in a step T-junction microdevice. Chin J Chem Eng 2021. [DOI: 10.1016/j.cjche.2021.07.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Ovdiichuk O, Mallapura H, Pineda F, Hourtané V, Långström B, Halldin C, Nag S, Maskali F, Karcher G, Collet C. Implementation of iMiDEV™, a new fully automated microfluidic platform for radiopharmaceutical production. LAB ON A CHIP 2021; 21:2272-2282. [PMID: 33912890 DOI: 10.1039/d1lc00148e] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
iMiDEV™ microfluidic system is a new automated tool for a small-scale production of radiopharmaceuticals. This new radiochemistry module utilizes microfluidic cassettes capable of producing diversified radiopharmaceuticals in liquid phase reactions in an automated synthesizer. The user interface is intuitive and designed to give the operator all the information required and to allow driving the synthesis either manually or fully automatically. In this work, we have demonstrated liquid phase reaction and presented the first results of an efficient fully automated [18F]NaF radiosynthesis on the iMiDEV™ platform. Different parameters such as a type of cyclotron targets, initial activity, concentration and volume of the fluoride-18 targetry have been investigated in order to elaborate the optimised radiolabelling of the ligand. Single and double sodium [18F]fluoride synthesis procedures have been successfully developed using two chambers of the cassette. A single-dose of radiotracer was produced in an average radiochemical yield of 87% (decay corrected) within 8 min and quality control tests were performed as per European Pharmacopoeia.
Collapse
Affiliation(s)
- Olga Ovdiichuk
- Nancyclotep, Molecular Imaging Platform, 5 rue du Morvan, F-54500 Vandoeuvre les Nancy, France.
| | - Hemantha Mallapura
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm 17176, Sweden
| | - Florian Pineda
- PMB Alcen, Route des Michels CD56, F-13790 Peynier, France
| | | | | | - Christer Halldin
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm 17176, Sweden
| | - Sangram Nag
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm 17176, Sweden
| | - Fatiha Maskali
- Nancyclotep, Molecular Imaging Platform, 5 rue du Morvan, F-54500 Vandoeuvre les Nancy, France.
| | - Gilles Karcher
- Nancyclotep, Molecular Imaging Platform, 5 rue du Morvan, F-54500 Vandoeuvre les Nancy, France. and CHRU-Nancy, Department of Nuclear Medicine, F-54000, Vandoeuvre les Nancy, France
| | - Charlotte Collet
- Nancyclotep, Molecular Imaging Platform, 5 rue du Morvan, F-54500 Vandoeuvre les Nancy, France. and INSERM U1254 IADI, Université de Lorraine, F-54500 Vandoeuvre les Nancy, France
| |
Collapse
|
16
|
Rios A, Holloway TS, Wang J, van Dam RM. Optimization of Radiochemical Reactions using Droplet Arrays. J Vis Exp 2021:10.3791/62056. [PMID: 33645586 PMCID: PMC8253531 DOI: 10.3791/62056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Current automated radiosynthesizers are designed to produce large clinical batches of radiopharmaceuticals. They are not well suited for reaction optimization or novel radiopharmaceutical development since each data point involves significant reagent consumption, and contamination of the apparatus requires time for radioactive decay before the next use. To address these limitations, a platform for performing arrays of miniature droplet-based reactions in parallel, each confined within a surface-tension trap on a patterned polytetrafluoroethylene-coated silicon "chip", was developed. These chips enable rapid and convenient studies of reaction parameters including reagent concentrations, reaction solvent, reaction temperature and time. This platform permits the completion of hundreds of reactions in a few days with minimal reagent consumption, instead of taking months using a conventional radiosynthesizer.
Collapse
Affiliation(s)
- Alejandra Rios
- Physics and Biology in Medicine Interdepartmental Graduate Program, University of California Los Angeles (UCLA); Crump Institute of Molecular Imaging, UCLA
| | - Travis S Holloway
- Crump Institute of Molecular Imaging, UCLA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine
| | - Jia Wang
- Crump Institute of Molecular Imaging, UCLA; Department of Bioengineering, UCLA
| | - R Michael van Dam
- Physics and Biology in Medicine Interdepartmental Graduate Program, University of California Los Angeles (UCLA); Crump Institute of Molecular Imaging, UCLA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine; Department of Bioengineering, UCLA;
| |
Collapse
|
17
|
Miyaoka RS, Lehnert A. Small animal PET: a review of what we have done and where we are going. Phys Med Biol 2020; 65. [PMID: 32357344 DOI: 10.1088/1361-6560/ab8f71] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 05/01/2020] [Indexed: 02/07/2023]
Abstract
Small animal research is an essential tool in studying both pharmaceutical biodistributions and disease progression over time. Furthermore, through the rapid development of in vivo imaging technology over the last few decades, small animal imaging (also referred to as preclinical imaging) has become a mainstay for all fields of biologic research and a center point for most preclinical cancer research. Preclinical imaging modalities include optical, MRI and MRS, microCT, small animal PET, ultrasound, and photoacoustic, each with their individual strengths. The strong points of small animal PET are its translatability to the clinic; its quantitative imaging capabilities; its whole-body imaging ability to dynamically trace functional/biochemical processes; its ability to provide useful images with only nano- to pico‑ molar concentrations of administered compounds; and its ability to study animals serially over time. This review paper gives an overview of the development and evolution of small animal PET imaging. It provides an overview of detector designs; system configurations; multimodality PET imaging systems; image reconstruction and analysis tools; and an overview of research and commercially available small animal PET systems. It concludes with a look toward developing technologies/methodologies that will further enhance the impact of small animal PET imaging on medical research in the future.
Collapse
Affiliation(s)
- Robert S Miyaoka
- Radiology, University of Washington, Seattle, Washington, UNITED STATES
| | - Adrienne Lehnert
- Radiology, University of Washington, Seattle, Washington, UNITED STATES
| |
Collapse
|
18
|
Jones J, Ha NS, Barajas AG, Chatziioannou AF, van Dam RM. Integration of High-Resolution Radiation Detector for Hybrid Microchip Electrophoresis. Anal Chem 2020; 92:3483-3491. [PMID: 31986878 PMCID: PMC7410349 DOI: 10.1021/acs.analchem.9b04827] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
For decades, there has been immense progress in miniaturizing analytical methods based on electrophoresis to improve sensitivity and to reduce sample volumes, separation times, and/or equipment cost and space requirements, in applications ranging from analysis of biological samples to environmental analysis to forensics. In the field of radiochemistry, where radiation-shielded laboratory space is limited, there has been great interest in harnessing the compactness, high efficiency, and speed of microfluidics to synthesize short-lived radiolabeled compounds. We recently proposed that analysis of these compounds could also benefit from miniaturization and have been investigating capillary electrophoresis (CE) and hybrid microchip electrophoresis (hybrid-MCE) as alternatives to the typically used high-performance liquid chromatography (HPLC). We previously showed separation of the positron-emission tomography (PET) imaging tracer 3'-deoxy-3'-fluorothymidine (FLT) from its impurities in a hybrid-MCE device with UV detection, with similar separation performance to HPLC, but with improved speed and lower sample volumes. In this paper, we have developed an integrated radiation detector to enable measurement of the emitted radiation from radiolabeled compounds. Though conventional radiation detectors have been incorporated into CE systems in the past, these approaches cannot be readily integrated into a compact hybrid-MCE device. We instead employed a solid-state avalanche photodiode (APD)-based detector for real-time, high-sensitivity β particle detection. The integrated system can reliably separate [18F]FLT from its impurities and perform chemical identification via coinjection with nonradioactive reference standard. This system can quantitate samples with radioactivity concentrations as low as 114 MBq/mL (3.1 mCi/mL), which is sufficient for analysis of radiochemical purity of radiopharmaceuticals.
Collapse
Affiliation(s)
- Jason Jones
- Crump Institute for Molecular Imaging and Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
- Physics & Biology in Medicine Interdepartmental
Graduate Program, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, CA 90095, USA
| | - Noel S. Ha
- Crump Institute for Molecular Imaging and Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
- Department of Bioengineering, Henry Samueli School of
Engineering and Applied Science, University of California Los Angeles, Los Angeles,
CA 90095, USA
| | - Alec G. Barajas
- Crump Institute for Molecular Imaging and Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
- Department of Chemistry & Biochemistry, University of
California Los Angeles, Los Angeles, CA 90095, USA
| | - Arion F. Chatziioannou
- Crump Institute for Molecular Imaging and Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
- Physics & Biology in Medicine Interdepartmental
Graduate Program, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, CA 90095, USA
- Department of Molecular & Medical Pharmacology,
University of California Los Angeles, Los Angeles, CA 90095, USA
| | - R. Michael van Dam
- Crump Institute for Molecular Imaging and Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of
California Los Angeles, Los Angeles, CA 90095, USA
- Physics & Biology in Medicine Interdepartmental
Graduate Program, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, CA 90095, USA
- Department of Bioengineering, Henry Samueli School of
Engineering and Applied Science, University of California Los Angeles, Los Angeles,
CA 90095, USA
- Department of Molecular & Medical Pharmacology,
University of California Los Angeles, Los Angeles, CA 90095, USA
| |
Collapse
|
19
|
Wang J, Holloway T, Lisova K, van Dam RM. Green and efficient synthesis of the radiopharmaceutical [ 18F]FDOPA using a microdroplet reactor. REACT CHEM ENG 2020; 5:320-329. [PMID: 34164154 PMCID: PMC8218909 DOI: 10.1039/c9re00354a] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
From an efficiency standpoint, microdroplet reactors enable significant improvements in the preparation of radiopharmaceuticals due to the vastly reduced reaction volume. To demonstrate these advantages, we adapt the conventional (macroscale) synthesis of the clinically-important positron-emission tomography tracer [18F]FDOPA, following the nucleophilic diaryliodonium salt approach, to a newly-developed ultra-compact microdroplet reaction platform. In this first microfluidic implementation of [18F]FDOPA synthesis, optimized via a high-throughput multi-reaction platform, the radiochemical yield (non-decay-corrected) was found to be comparable to macroscale reports, but the synthesis consumed significantly less precursor and organic solvents, and the synthesis process was much faster. In this initial report, we demonstrate the production of [18F]FDOPA in 15 MBq [400 μCi] amounts, sufficient for imaging of multiple mice, at high molar activity.
Collapse
Affiliation(s)
- Jia Wang
- Department of Bioengineering, Henry Samueli School of Engineering
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
- Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA, USA
| | - Travis Holloway
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
- Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA, USA
| | - Ksenia Lisova
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
- Physics in Biology and Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
- Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA, USA
| | - R Michael van Dam
- Department of Bioengineering, Henry Samueli School of Engineering
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
- Physics in Biology and Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
- Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA, USA
| |
Collapse
|
20
|
Gaudeau M, Zhang M, Tatoulian M, Lescot C, Ognier S. Fast carbonylation reaction from CO 2 using plasma gas/liquid microreactors for radiolabeling applications. REACT CHEM ENG 2020. [DOI: 10.1039/d0re00289e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The major challenge for 11C-radiolabelling is the short half-life time of 11C (t1/2 = 20.4 min) – in this study, a novel efficient process combining microfluidics and plasma is proposed for fast carbonylation reactions from CO2.
Collapse
Affiliation(s)
- Marion Gaudeau
- Chimie ParisTech-PSL
- PSL Université Paris
- CNRS
- Institut de Recherche de Chimie Paris
- 75005 Paris
| | - Mengxue Zhang
- Chimie ParisTech-PSL
- PSL Université Paris
- CNRS
- Institut de Recherche de Chimie Paris
- 75005 Paris
| | - Michaël Tatoulian
- Chimie ParisTech-PSL
- PSL Université Paris
- CNRS
- Institut de Recherche de Chimie Paris
- 75005 Paris
| | - Camille Lescot
- Chimie ParisTech-PSL
- PSL Université Paris
- CNRS
- 75005 Paris
- France
| | - Stéphanie Ognier
- Chimie ParisTech-PSL
- PSL Université Paris
- CNRS
- Institut de Recherche de Chimie Paris
- 75005 Paris
| |
Collapse
|
21
|
Wang J, van Dam RM. High-Efficiency Production of Radiopharmaceuticals via Droplet Radiochemistry: A Review of Recent Progress. Mol Imaging 2020; 19:1536012120973099. [PMID: 33296272 PMCID: PMC7731702 DOI: 10.1177/1536012120973099] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 09/02/2020] [Accepted: 10/12/2020] [Indexed: 12/13/2022] Open
Abstract
New platforms are enabling radiochemistry to be carried out in tiny, microliter-scale volumes, and this capability has enormous benefits for the production of radiopharmaceuticals. These droplet-based technologies can achieve comparable or better yields compared to conventional methods, but with vastly reduced reagent consumption, shorter synthesis time, higher molar activity (even for low activity batches), faster purification, and ultra-compact system size. We review here the state of the art of this emerging direction, summarize the radiotracers and prosthetic groups that have been synthesized in droplet format, describe recent achievements in scaling up activity levels, and discuss advantages and limitations and the future outlook of these innovative devices.
Collapse
Affiliation(s)
- Jia Wang
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, USA
| | - R. Michael van Dam
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, USA
| |
Collapse
|
22
|
Lisova K, Chen BY, Wang J, Fong KMM, Clark PM, van Dam RM. Rapid, efficient, and economical synthesis of PET tracers in a droplet microreactor: application to O-(2-[ 18F]fluoroethyl)-L-tyrosine ([ 18F]FET). EJNMMI Radiopharm Chem 2019; 5:1. [PMID: 31893318 PMCID: PMC6938530 DOI: 10.1186/s41181-019-0082-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 11/21/2019] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Conventional scale production of small batches of PET tracers (e.g. for preclinical imaging) is an inefficient use of resources. Using O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), we demonstrate that simple microvolume radiosynthesis techniques can improve the efficiency of production by consuming tiny amounts of precursor, and maintaining high molar activity of the tracers even with low starting activity. PROCEDURES The synthesis was carried out in microvolume droplets manipulated on a disposable patterned silicon "chip" affixed to a heater. A droplet of [18F]fluoride containing TBAHCO3 was first deposited onto a chip and dried at 100 °C. Subsequently, a droplet containing 60 nmol of precursor was added to the chip and the fluorination reaction was performed at 90 °C for 5 min. Removal of protecting groups was accomplished with a droplet of HCl heated at 90 °C for 3 min. Finally, the crude product was collected in a methanol-water mixture, purified via analytical-scale radio-HPLC and formulated in saline. As a demonstration, using [18F]FET produced on the chip, we prepared aliquots with different molar activities to explore the impact on preclinical PET imaging of tumor-bearing mice. RESULTS The microdroplet synthesis exhibited an overall decay-corrected radiochemical yield of 55 ± 7% (n = 4) after purification and formulation. When automated, the synthesis could be completed in 35 min. Starting with < 370 MBq of activity, ~ 150 MBq of [18F]FET could be produced, sufficient for multiple in vivo experiments, with high molar activities (48-119 GBq/μmol). The demonstration imaging study revealed the uptake of [18F]FET in subcutaneous tumors, but no significant differences in tumor uptake as a result of molar activity differences (ranging 0.37-48 GBq/μmol) were observed. CONCLUSIONS A microdroplet synthesis of [18F]FET was developed demonstrating low reagent consumption, high yield, and high molar activity. The approach can be expanded to tracers other than [18F]FET, and adapted to produce higher quantities of the tracer sufficient for clinical PET imaging.
Collapse
Affiliation(s)
- Ksenia Lisova
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - Bao Ying Chen
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - Jia Wang
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA
| | - Kelly Mun-Ming Fong
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - Peter M Clark
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - R Michael van Dam
- Physics in Biology and Medicine Interdepartmental Graduate Program, University of California, Los Angeles, Los Angeles, CA, USA.
- Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, USA.
| |
Collapse
|
23
|
Investigation of microfluidic co-flow effects on step emulsification: Wall contact angle and critical dimensions. Colloids Surf A Physicochem Eng Asp 2019. [DOI: 10.1016/j.colsurfa.2019.123733] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Lei M, Pan JZ, Xu GM, Du PZ, Tian M, Zhang H. Automated microfluidic chip system for radiosynthesis of PET imaging probes. J Zhejiang Univ Sci B 2019; 20:865-867. [PMID: 31595722 DOI: 10.1631/jzus.b1900535] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Positron emission tomography (PET) is a powerful non-invasive molecular imaging technique for the early detection, characterization, and "real-time" monitoring of disease, and for investigating the efficacy of drugs (Phelps, 2000; Ametamey et al., 2008). The development of molecular probes bearing short-lived positron-emitting radionuclides, such as 18F (half-life 110 min) or 11C (half-life 20 min), is crucial for PET imaging to collect in vivo metabolic information in a time-efficient manner (Deng et al., 2019). In this regard, one of the main challenges is rapid synthesis of radiolabeled probes by introducing the radionuclides into pharmaceuticals as soon as possible before injection for a PET scan. Although many potential PET probes have been discovered, only a handful can satisfy the demand for a highly efficient synthesis procedure that achieves radiolabeling and delivery for imaging within 1-2 radioisotope half-lives. Only a few probes, such as 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) and [18F]fluorodopa, are routinely produced on a commercial scale for daily clinical diagnosis (Grayson et al., 2018; Carollo et al., 2019).
Collapse
Affiliation(s)
- Ming Lei
- PET Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.,Department of Chemistry, Zhejiang University, Hangzhou 310058, China.,Department of Nuclear Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
| | - Jian-Zhang Pan
- Department of Chemistry, Zhejiang University, Hangzhou 310058, China
| | - Guang-Ming Xu
- Department of Chemistry, Zhejiang University, Hangzhou 310058, China
| | - Pei-Zhen Du
- PET Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.,Department of Nuclear Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
| | - Mei Tian
- PET Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.,Department of Nuclear Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
| | - Hong Zhang
- PET Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.,Department of Nuclear Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.,Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China
| |
Collapse
|
25
|
Frank C, Winter G, Rensei F, Samper V, Brooks AF, Hockley BG, Henderson BD, Rensch C, Scott PJH. Development and implementation of ISAR, a new synthesis platform for radiopharmaceutical production. EJNMMI Radiopharm Chem 2019; 4:24. [PMID: 31659546 PMCID: PMC6751239 DOI: 10.1186/s41181-019-0077-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 08/30/2019] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND PET radiopharmaceutical development and the implementation of a production method on a synthesis module is a complex and time-intensive task since new synthesis methods must be adapted to the confines of the synthesis platform in use. Commonly utilized single fluid bus architectures put multiple constraints on synthesis planning and execution, while conventional microfluidic solutions are limited by compatibility at the macro-to-micro interface. In this work we introduce the ISAR synthesis platform and custom-tailored fluid paths leveraging up to 70 individually addressable valves on a chip-based consumable. The ISAR synthesis platform replaces traditional stopcock valve manifolds with a fluidic chip that integrates all fluid paths (tubing) and valves into one consumable and enables channel routing without the single fluid bus constraint. ISAR can scale between the macro- (10 mL), meso- (0.5 mL) and micro- (≤0.05 mL) domain seamlessly, addressing the macro-to-micro interface challenge and enabling custom tailored fluid circuits for a given application. In this paper we demonstrate proof-of-concept by validating a single chip design to address the challenge of synthesizing multiple batches of [13N]NH3 for clinical use throughout the workday. RESULTS ISAR was installed at an academic PET Center and used to manufacture [13N]NH3 in > 96% radiochemical yield. Up to 9 batches were manufactured with a single consumable chip having parallel paths without the need to open the hot-cell. Quality control testing confirmed the ISAR-based [13N]NH3 met existing clinical release specifications, and utility was demonstrated by imaging a rodent with [13N]NH3 produced on ISAR. CONCLUSIONS ISAR represents a new paradigm in radiopharmaceutical production. Through a new system architecture, ISAR integrates the principles of microfluidics with the standard volumes and consumables established in PET Centers all over the world. Proof-of-concept has been demonstrated through validation of a chip design for the synthesis of [13N]NH3 suitable for clinical use.
Collapse
Affiliation(s)
| | - Georg Winter
- GE Healthcare, Oskar-Schlemmer-Str. 11, 80807 Munich, Germany
| | | | | | - Allen F. Brooks
- Department of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI 48109 USA
| | - Brian G. Hockley
- Department of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI 48109 USA
| | - Bradford D. Henderson
- Department of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI 48109 USA
| | | | - Peter J. H. Scott
- Department of Radiology, University of Michigan, 2276 Medical Science Bldg I, SPC 5610, Ann Arbor, MI 48109 USA
| |
Collapse
|
26
|
Knapp KA, Nickels ML, Manning HC. The Current Role of Microfluidics in Radiofluorination Chemistry. Mol Imaging Biol 2019; 22:463-475. [DOI: 10.1007/s11307-019-01414-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
27
|
Wang J, Chao PH, van Dam RM. Ultra-compact, automated microdroplet radiosynthesizer. LAB ON A CHIP 2019; 19:2415-2424. [PMID: 31187109 PMCID: PMC7416997 DOI: 10.1039/c9lc00438f] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Application of microfluidics offers numerous advantages in the field of radiochemistry and could enable dramatic reductions in the cost of producing radiotracers for positron emission tomography (PET). Droplet-based microfluidics, in particular, requires only microgram quantities of expensive precursors and reagents (compared to milligram used in conventional radiochemistry systems), and occupies a more compact footprint (potentially eliminating the need for specialized shielding facilities, i.e. hot cells). However, the reported platforms for droplet radiosynthesis have several drawbacks, including high cost/complexity of microfluidic reactors, requirement for manual intervention (e.g. for adding reagents), or difficulty in precise control of droplet processes. We describe here a platform based on a particularly simple chip, where reactions take place atop a hydrophobic substrate patterned with a circular hydrophilic liquid trap. The overall supporting hardware (heater, rotating carousel of reagent dispensers, etc.) is very simple and the whole system could be packaged into a very compact format (about the size of a coffee cup). We demonstrate the consistent synthesis of [18F]fallypride with high yield, and show that protocols optimized using a high-throughput optimization platform we have developed can be readily translated to this device with no changes or re-optimization. We are currently exploring the use of this platform for routine production of a variety of 18F-labeled tracers for preclinical imaging and for production of tracers in clinically-relevant amounts by integrating the system with an upstream radionuclide concentrator.
Collapse
Affiliation(s)
- Jia Wang
- Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA. and Department of Bioengineering, UCLA, Los Angeles, CA, USA
| | - Philip H Chao
- Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA. and Department of Bioengineering, UCLA, Los Angeles, CA, USA
| | - R Michael van Dam
- Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA. and Department of Bioengineering, UCLA, Los Angeles, CA, USA
| |
Collapse
|
28
|
Rios A, Wang J, Chao PH, van Dam RM. A novel multi-reaction microdroplet platform for rapid radiochemistry optimization. RSC Adv 2019; 9:20370-20374. [PMID: 35514735 PMCID: PMC9065505 DOI: 10.1039/c9ra03639c] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 06/17/2019] [Indexed: 12/20/2022] Open
Abstract
During the development of novel tracers for positron emission tomography (PET), the optimization of the synthesis is hindered by practical limitations on the number of experiments that can be performed per day. Here we present a microliter droplet chip that contains multiple sites (4 or 16) to perform reactions simultaneously under the same or different conditions to accelerate radiosynthesis optimization. Multi-reaction microdroplet chip enables rapid radiotracer optimization for positron emission tomography.![]()
Collapse
Affiliation(s)
- Alejandra Rios
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA) Los Angeles CA USA .,Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA USA
| | - Jia Wang
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA) Los Angeles CA USA .,Department of Bioengineering, UCLA USA
| | - Philip H Chao
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA) Los Angeles CA USA .,Department of Bioengineering, UCLA USA
| | - R Michael van Dam
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA) Los Angeles CA USA .,Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA USA.,Department of Bioengineering, UCLA USA.,Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA USA
| |
Collapse
|
29
|
Hong H, Zhang L, Xie F, Zhuang R, Jiang D, Liu H, Li J, Yang H, Zhang X, Nie L, Li Z. Rapid one-step 18F-radiolabeling of biomolecules in aqueous media by organophosphine fluoride acceptors. Nat Commun 2019; 10:989. [PMID: 30824691 PMCID: PMC6397219 DOI: 10.1038/s41467-019-08953-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 02/07/2019] [Indexed: 11/19/2022] Open
Abstract
Currently, only a few 18F-radiolabeling methods were conducted in aqueous media, with non-macroelement fluoride acceptors and stringent conditions required. Herein, we describe a one-step non-solvent-biased, room-temperature-driven 18F-radiolabeling methodology based on organophosphine fluoride acceptors. The high water tolerance for this isotope-exchange-based 18F-labeling method is attributed to the kinetic and thermodynamic preference of F/F over the OH/F substitution based on computational calculations and experimental validation. Compact [18/19F]di-tert-butyl-organofluorophosphine and its derivatives used as 18F-labeling synthons exhibit excellent stability in vivo. The synthons are further conjugated to several biomolecular ligands such as c(RGDyk) and human serum albumin. The one-step labeled biomolecular tracers demonstrate intrinsic target imaging ability and negligible defluorination in vivo. The current method thus offers a facile and efficient 18F-radiolabeling pathway, enabling further widespread application of 18F. The synthesis of 18F-labeled positron emission tomography (PET) tracers is difficult and typically requires anhydrous conditions. Here, the authors developed organophosphine precursors that allow for quick, high-yield synthesis of 18F-labeled probes in either organic solvents or aqueous media.
Collapse
Affiliation(s)
- Huawei Hong
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Lei Zhang
- Tianjin Engineering Technology Center of Chemical Wastewater Source Reduction and Recycling, School of Science, Tianjin Chengjian University, 300384, Tianjin, China
| | - Fang Xie
- PET center, Huashan Hospital, Fudan University, 200235, Shanghai, China
| | - Rongqiang Zhuang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Donglang Jiang
- PET center, Huashan Hospital, Fudan University, 200235, Shanghai, China
| | - Huanhuan Liu
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Jindian Li
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Hongzhang Yang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Xianzhong Zhang
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China
| | - Liming Nie
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China.
| | - Zijing Li
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, Fujian, China.
| |
Collapse
|
30
|
Chao PH, Lazari M, Hanet S, Narayanam MK, Murphy JM, van Dam RM. Automated concentration of [ 18F]fluoride into microliter volumes. Appl Radiat Isot 2018; 141:138-148. [PMID: 30243135 PMCID: PMC6502507 DOI: 10.1016/j.apradiso.2018.06.017] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2018] [Revised: 06/07/2018] [Accepted: 06/20/2018] [Indexed: 11/23/2022]
Abstract
Concentration of [18F]fluoride has been mentioned in literature, however, reports have lacked details about system designs, operation, and performance. Here, we describe in detail a compact, fast, fully-automated concentration system based on a micro-sized strong anion exchange cartridge. The concentration of radionuclides enables scaled-up microfluidic synthesis. Our system can also be used to provide highly concentrated [18F]fluoride with minimal water content. We demonstrate how the concentrator can produce varying concentrations of [18F]fluoride for the macroscale synthesis of N-boc-5-[18F]fluoroindole without an azeotropic drying process, while enabling high starting radioactivity. By appropriate choice of solid-phase resin, flow conditions, and eluent solution, we believe this approach can be extended beyond [18F]fluoride to other radionuclides.
Collapse
Affiliation(s)
- Philip H Chao
- Department of Bioengineering, Henry Samueli School of Engineering, UCLA, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Mark Lazari
- Department of Bioengineering, Henry Samueli School of Engineering, UCLA, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Sebastian Hanet
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Maruthi Kumar Narayanam
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | - Jennifer M Murphy
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | - R Michael van Dam
- Department of Bioengineering, Henry Samueli School of Engineering, UCLA, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| |
Collapse
|
31
|
Tarn MD, Kızılyer NY, Esfahani MMN, Joshi P, Brown NJ, Pamme N, Jenkins DG, Archibald SJ. Plastic Scintillator-Based Microfluidic Devices for Miniaturized Detection of Positron Emission Tomography Radiopharmaceuticals. Chemistry 2018; 24:13749-13753. [DOI: 10.1002/chem.201802395] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 07/06/2018] [Indexed: 12/14/2022]
Affiliation(s)
- Mark D. Tarn
- Positron Emission Tomography Research Centre; University of Hull; Cottingham Road Hull HU6 7RX UK
- School of Mathematics and Physical Sciences; University of Hull; Cottingham Road Hull HU6 7RX UK
- Current address: School of Earth and Environment; University of Leeds; Woodhouse Lane Leeds LS2 9JT UK
| | - Nuray Yavuzkanat Kızılyer
- Department of Physics; University of York; Heslington York YO10 5DD UK
- Current address: Faculty of Art and Science; Bitlis Eren University; Bitlis 13000 Turkey
| | - Mohammad M. N. Esfahani
- Positron Emission Tomography Research Centre; University of Hull; Cottingham Road Hull HU6 7RX UK
- School of Engineering and Computer Science; University of Hull; Cottingham Road Hull HU6 7RX UK
| | - Pankaj Joshi
- Department of Physics; University of York; Heslington York YO10 5DD UK
| | - Nathaniel J. Brown
- School of Engineering and Computer Science; University of Hull; Cottingham Road Hull HU6 7RX UK
| | - Nicole Pamme
- School of Mathematics and Physical Sciences; University of Hull; Cottingham Road Hull HU6 7RX UK
| | - David G. Jenkins
- Department of Physics; University of York; Heslington York YO10 5DD UK
| | - Stephen J. Archibald
- Positron Emission Tomography Research Centre; University of Hull; Cottingham Road Hull HU6 7RX UK
- School of Mathematics and Physical Sciences; University of Hull; Cottingham Road Hull HU6 7RX UK
| |
Collapse
|
32
|
Molecular imaging in dementia: Past, present, and future. Alzheimers Dement 2018; 14:1522-1552. [DOI: 10.1016/j.jalz.2018.06.2855] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Revised: 06/02/2018] [Accepted: 06/03/2018] [Indexed: 12/14/2022]
|
33
|
|
34
|
Lisova K, Sergeev M, Evans-Axelsson S, Stuparu AD, Beykan S, Collins J, Jones J, Lassmann M, Herrmann K, Perrin D, Lee JT, Slavik R, van Dam RM. Microscale radiosynthesis, preclinical imaging and dosimetry study of [ 18F]AMBF 3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 2018; 61:36-44. [PMID: 29747035 DOI: 10.1016/j.nucmedbio.2018.04.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 03/28/2018] [Accepted: 04/01/2018] [Indexed: 02/08/2023]
Abstract
BACKGROUND Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. Recent developments have greatly simplified such labeling: in particular, labeling of organotrifluoroborates via isotopic exchange can readily be performed in a single-step under aqueous conditions and without the need for HPLC purification. Though an automated synthesis has not yet been explored, microfluidic approaches have emerged for 18F-labeling with high speed, minimal reagents, and high molar activity compared to conventional approaches. As a proof-of-concept, we performed microfluidic labeling of an octreotate analog ([18F]AMBF3-TATE), a promising 18F-labeled analog that could compete with [68Ga]Ga-DOTATATE with the advantage of providing a greater number of patient doses per batch produced. METHODS Both [18F]AMBF3-TATE and [68Ga]Ga-DOTATATE were labeled, the former by microscale methods adapted from manual labeling, and were imaged in mice bearing human SSTR2-overexpressing, rat SSTR2 wildtype, and SSTR2-negative xenografts. Furthermore, a dosimetry analysis was performed for [18F]AMBF3-TATE. RESULTS The micro-synthesis exhibited highly-repeatable performance with radiochemical conversion of 50 ± 6% (n = 15), overall decay-corrected radiochemical yield of 16 ± 1% (n = 5) in ~40 min, radiochemical purity >99%, and high molar activity. Preclinical imaging with [18F]AMBF3-TATE in SSTR2 tumor models correlated well with [68Ga]Ga-DOTATATE. The favorable biodistribution, with the highest tracer accumulation in the bladder followed distantly by gastrointestinal tissues, resulted in 1.26 × 10-2 mSv/MBq maximal estimated effective dose in human, a value lower than that reported for current clinical 18F- and 68Ga-labeled compounds. CONCLUSIONS The combination of novel chemical approaches to 18F-labeling and microdroplet radiochemistry have the potential to serve as a platform for greatly simplified development and production of 18F-labeled peptide tracers. Favorable preclinical imaging and dosimetry of [18F]AMBF3-TATE, combined with a convenient synthesis, validate this assertion and suggest strong potential for clinical translation.
Collapse
Affiliation(s)
- Ksenia Lisova
- Physics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Maxim Sergeev
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Susan Evans-Axelsson
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Andreea D Stuparu
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Seval Beykan
- Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
| | - Jeffrey Collins
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Jason Jones
- Physics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Michael Lassmann
- Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
| | - Ken Herrmann
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA
| | - David Perrin
- Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
| | - Jason T Lee
- Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA.
| | - Roger Slavik
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA.
| | - R Michael van Dam
- Physics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA.
| |
Collapse
|
35
|
Matesic L, Greguric I, Pascali G. Microfluidic Radiosynthesis of the Muscarinic M2 Imaging Agent [18F]FP-TZTP. Aust J Chem 2018. [DOI: 10.1071/ch18266] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
3-(4-(3-[18F]Fluoropropylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine ([18F]FP-TZTP) is a selective 18F-radiotracer for the muscarinic acetylcholine receptor subtype M2, which can be used to perform positron emission tomography (PET) scans on patients with neurological disorders such as Alzheimer’s disease. [18F]FP-TZTP was produced using continuous-flow microfluidics, a technique that uses reduced amounts of chemical reagents, shorter reaction times and in general, results in higher radiochemical yields compared to currently used techniques. The optimal 18F-radiolabelling conditions consisted of a total flow rate of 40 µL min−1 and 190°C, which produced [18F]FP-TZTP in 26 ± 10 % radiochemical yield with a molar activity of 182 ± 65 GBq µmol−1 and >99 % radiochemical purity.
Collapse
|
36
|
Collier TL, Liang SH, Mann JJ, Vasdev N, Kumar JSD. Microfluidic radiosynthesis of [ 18F]FEMPT, a high affinity PET radiotracer for imaging serotonin receptors. Beilstein J Org Chem 2017; 13:2922-2927. [PMID: 29564020 PMCID: PMC5753126 DOI: 10.3762/bjoc.13.285] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 12/18/2017] [Indexed: 01/04/2023] Open
Abstract
Continuous-flow microfluidics has shown increased applications in radiochemistry over the last decade, particularly for both pre-clinical and clinical production of fluorine-18 labeled radiotracers. The main advantages of microfluidics are the reduction in reaction times and consumption of reagents that often result in increased radiochemical yields and rapid optimization of reaction parameters for 18F-labeling. In this paper, we report on the two-step microfluidic radiosynthesis of the high affinity partial agonist of the serotonin 1A receptor, [18F]FEMPT (pKi = 9. 79; Ki = 0.16 nM) by microfluidic radiochemistry. [18F]FEMPT was obtained in ≈7% isolated radiochemical yield and in >98% radiochemical and chemical purity. The molar activity of the final product was determined to be >148 GBq/µmol (>4 Ci/µmol).
Collapse
Affiliation(s)
- Thomas Lee Collier
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
- Advion, Inc., Ithaca, NY, USA
| | - Steven H Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
| | - J John Mann
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, NY, USA
| | | | - J S Dileep Kumar
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, NY, USA
| |
Collapse
|
37
|
Ha NS, Sadeghi S, van Dam RM. Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals. MICROMACHINES 2017; 8:E337. [PMID: 30400527 PMCID: PMC6190332 DOI: 10.3390/mi8110337] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 11/08/2017] [Accepted: 11/18/2017] [Indexed: 01/18/2023]
Abstract
Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.
Collapse
Affiliation(s)
- Noel S Ha
- Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| | - Saman Sadeghi
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| | - R Michael van Dam
- Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| |
Collapse
|
38
|
Matesic L, Kallinen A, Greguric I, Pascali G. Dose-on-demand production of diverse 18 F-radiotracers for preclinical applications using a continuous flow microfluidic system. Nucl Med Biol 2017; 52:24-31. [DOI: 10.1016/j.nucmedbio.2017.05.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 05/08/2017] [Accepted: 05/10/2017] [Indexed: 12/30/2022]
|
39
|
Klenner MA, Pascali G, Zhang B, Sia TR, Spare LK, Krause‐Heuer AM, Aldrich‐Wright JR, Greguric I, Guastella AJ, Massi M, Fraser BH. A Fluorine‐18 Radiolabeling Method Enabled by Rhenium(I) Complexation Circumvents the Requirement of Anhydrous Conditions. Chemistry 2017; 23:6499-6503. [DOI: 10.1002/chem.201700440] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2017] [Indexed: 11/06/2022]
Affiliation(s)
- Mitchell A. Klenner
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
- Department of Chemistry Curtin University Kent St Bentley Western Australia Australia
| | - Giancarlo Pascali
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
- Brain and Mind Centre The University of Sydney Mallett St Camperdown New South Wales Australia
| | - Bo Zhang
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
- Monash University Wellington Road Clayton Victoria Australia
| | - Tiffany R. Sia
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
- Brain and Mind Centre The University of Sydney Mallett St Camperdown New South Wales Australia
| | - Lawson K. Spare
- School of Science and Health Western Sydney University Penrith New South Wales Australia
| | - Anwen M. Krause‐Heuer
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
| | | | - Ivan Greguric
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
| | - Adam J. Guastella
- Brain and Mind Centre The University of Sydney Mallett St Camperdown New South Wales Australia
| | - Massimiliano Massi
- Department of Chemistry Curtin University Kent St Bentley Western Australia Australia
| | - Benjamin H. Fraser
- Australian Nuclear Science and Technology Organisation (ANSTO) New Illawarra Rd Lucas Heights New South Wales Australia
| |
Collapse
|
40
|
Whittenberg JJ, Li H, Zhou H, Koziol J, Desai AV, Reichert DE, Kenis PJA. “Click Chip” Conjugation of Bifunctional Chelators to Biomolecules. Bioconjug Chem 2017; 28:986-994. [DOI: 10.1021/acs.bioconjchem.6b00703] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Joseph J. Whittenberg
- Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana−Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States
| | - Hairong Li
- Radiological
Sciences Division, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus Box 8225, St. Louis, Missouri 63110, United States
| | - Haiying Zhou
- Radiological
Sciences Division, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus Box 8225, St. Louis, Missouri 63110, United States
| | - Jan Koziol
- Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana−Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States
| | - Amit V. Desai
- Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana−Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States
| | - David E. Reichert
- Radiological
Sciences Division, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus Box 8225, St. Louis, Missouri 63110, United States
| | - Paul J. A. Kenis
- Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana−Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States
| |
Collapse
|
41
|
Liu Z, Schaap KS, Ballemans L, de Zanger R, de Blois E, Rohde M, Oehlke E. Measurement of reaction kinetics of [177Lu]Lu-DOTA-TATE using a microfluidic system. Dalton Trans 2017; 46:14669-14676. [DOI: 10.1039/c7dt01830d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Design and evaluation of a microfluidic system that allowed the determination of Arrhenius parameters for the formation of [177Lu]Lu-DOTA-TATE using clinical radiolabeling conditions.
Collapse
Affiliation(s)
- Z. Liu
- Delft University of Technology
- Department Radiation Science and Technology
- 2629JB Delft
- The Netherlands
| | - K. S. Schaap
- Delft University of Technology
- Department Radiation Science and Technology
- 2629JB Delft
- The Netherlands
| | - L. Ballemans
- Delft University of Technology
- Department Radiation Science and Technology
- 2629JB Delft
- The Netherlands
| | - R. de Zanger
- Erasmus MC
- Department of Radiology and Nuclear Medicine
- 3015CN Rotterdam
- The Netherlands
| | - E. de Blois
- Erasmus MC
- Department of Radiology and Nuclear Medicine
- 3015CN Rotterdam
- The Netherlands
| | - M. Rohde
- Delft University of Technology
- Department Radiation Science and Technology
- 2629JB Delft
- The Netherlands
| | - E. Oehlke
- Delft University of Technology
- Department Radiation Science and Technology
- 2629JB Delft
- The Netherlands
| |
Collapse
|
42
|
Taggart MP, Tarn MD, Esfahani MMN, Schofield DM, Brown NJ, Archibald SJ, Deakin T, Pamme N, Thompson LF. Development of radiodetection systems towards miniaturised quality control of PET and SPECT radiopharmaceuticals. LAB ON A CHIP 2016; 16:1605-1616. [PMID: 27044712 DOI: 10.1039/c6lc00099a] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The ability to detect radiation in microfluidic devices is important for the on-chip analysis of radiopharmaceuticals, but previously reported systems have largely suffered from various limitations including cost, complexity of fabrication, and insufficient sensitivity and/or speed. Here, we present the use of sensitive, low cost, small-sized, commercially available silicon photomultipliers (SiPMs) for the detection of radioactivity inside microfluidic channels fabricated from a range of conventional microfluidic chip substrates. We demonstrate the effects of chip material and thickness on the detection of the positron-emitting isotope, [(18)F]fluoride, and find that, while the SiPMs are light sensors, they are able to detect radiation even through opaque chip materials via direct positron and gamma (γ) ray interaction. Finally, we employed the SiPM platform for analysis of the PET (positron emission tomography) radiotracers 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) and [(68)Ga]gallium-citrate, and highlight the ability to detect the γ ray emitting SPECT (single photon emission computed tomography) radiotracer, [(99m)Tc]pertechnetate.
Collapse
Affiliation(s)
- Matthew P Taggart
- Department of Physics and Astronomy, University of Sheffield, Hounsfield Road, Sheffield, S3 7RH, UK.
| | - Mark D Tarn
- Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Department of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.
| | | | - Daniel M Schofield
- LabLogic Systems Ltd., Paradigm House, 3 Melbourne Avenue, Broomhill, Sheffield, S10 2QJ, UK
| | - Nathaniel J Brown
- School of Engineering, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Stephen J Archibald
- Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Department of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.
| | - Tom Deakin
- Department of Physics and Astronomy, University of Sheffield, Hounsfield Road, Sheffield, S3 7RH, UK. and LabLogic Systems Ltd., Paradigm House, 3 Melbourne Avenue, Broomhill, Sheffield, S10 2QJ, UK
| | - Nicole Pamme
- Department of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.
| | - Lee F Thompson
- Department of Physics and Astronomy, University of Sheffield, Hounsfield Road, Sheffield, S3 7RH, UK.
| |
Collapse
|
43
|
Tarn MD, Maneuski D, Alexander R, Brown NJ, O’Shea V, Pimlott SL, Pamme N, Archibald SJ. Positron detection in silica monoliths for miniaturised quality control of PET radiotracers. Chem Commun (Camb) 2016; 52:7221-4. [DOI: 10.1039/c6cc00660d] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Real-time, high S/N radiodetection of the PET radiotracer, 68Ga-citrate, was achieved on a monolithic column using a miniaturised positron sensor.
Collapse
Affiliation(s)
- Mark D. Tarn
- Positron Emission Tomography Research Centre
- University of Hull
- Hull
- UK
- Department of Chemistry
| | | | | | | | - Val O’Shea
- School of Physics and Astronomy
- University of Glasgow
- Glasgow
- UK
| | | | | | - Stephen J. Archibald
- Positron Emission Tomography Research Centre
- University of Hull
- Hull
- UK
- Department of Chemistry
| |
Collapse
|
44
|
Lindner S, Rensch C, Neubaur S, Neumeier M, Salvamoser R, Samper V, Bartenstein P. Azeotropic drying free [18F]FDG synthesis and its application to a lab-on-chip platform. Chem Commun (Camb) 2016; 52:729-32. [DOI: 10.1039/c5cc07106b] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
[18F]FDG was prepared using a cartridge-based drying technique for [18F]fluoride. The application to a lab-on-chip platform demonstrates a proof of concept towards reduced hardware complexity.
Collapse
Affiliation(s)
- S. Lindner
- Department of Nuclear Medicine
- University Hospital Munich LMU
- 81377 Munich
- Germany
| | - C. Rensch
- GE Global Research
- 85748 Garching
- Germany
| | - S. Neubaur
- Department of Nuclear Medicine
- University Hospital Munich LMU
- 81377 Munich
- Germany
| | - M. Neumeier
- Department of Nuclear Medicine
- University Hospital Munich LMU
- 81377 Munich
- Germany
| | | | - V. Samper
- GE Global Research
- 85748 Garching
- Germany
| | - P. Bartenstein
- Department of Nuclear Medicine
- University Hospital Munich LMU
- 81377 Munich
- Germany
| |
Collapse
|
45
|
Abstract
The emerging technology of digital microfluidics is opening up the possibility of performing radiochemistry at the microliter scale to produce tracers for positron emission tomography (PET) labeled with fluorine-18 or other isotopes. Working at this volume scale not only reduces reagent costs but also improves specific activity (SA) by reducing contamination by the stable isotope. This technology could provide a practical means to routinely prepare high-SA tracers for applications such as neuroimaging and could make it possible to routinely achieve high SA using synthesis strategies such as isotopic exchange. Reagent droplets are controlled electronically, providing high reliability, a compact control system, and flexibility for diverse syntheses with a single-chip design. The compact size may enable the development of a self-shielded synthesizer that does not require a hot cell. This article reviews the progress of this technology and its application to the synthesis of PET tracers.
Collapse
Affiliation(s)
- Pei Yuin Keng
- Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology University of California, Los Angeles
| | - R. Michael van Dam
- Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology University of California, Los Angeles
| |
Collapse
|
46
|
Calderwood S, Collier TL, Gouverneur V, Liang SH, Vasdev N. Synthesis of 18F-Arenes from Spirocyclic Iodonium(III) Ylides via Continuous-Flow Microfluidics. J Fluor Chem 2015; 178:249-253. [PMID: 27512233 PMCID: PMC4976495 DOI: 10.1016/j.jfluchem.2015.08.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Spirocyclic hypervalent iodine(III) ylides have proven to be synthetically versatile precursors for efficient radiolabelling of a diverse range of non-activated (hetero)arenes, highly functionalised small molecules, building blocks and radiopharmaceuticals from [18F]fluoride ion. Herein, we report the implementation of these reactions onto a continuous-flow microfluidic platform, thereby offering an alterative and automated synthetic procedure of a radiopharmaceutical, 3-[18F]fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB) and a routinely used building block for click-radiochemistry, 4-[18F]fluorobenzyl azide. This new protocol was applied to the synthesis of [18F]FPEB (radiochemical conversion (RCC) = 68 ± 5%) and 4-[18F]fluorobenzyl azide (RCC=68 ± 5%; isolated radiochemical yield = 24±0%). We anticipate that the high throughput microfluidic platform will accelerate the discovery and applications of 18F-labelled building blocks and labelled compounds prepared by iodonium ylide precursors as well as the production of radiotracers for preclinical imaging studies.
Collapse
Affiliation(s)
- Samuel Calderwood
- University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, UK
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit Street, Boston, USA
| | - Thomas Lee Collier
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit Street, Boston, USA
- Department of Radiology, Harvard Medical School, 55 Fruit Street, Boston, USA
- Advion BioSystems, 10 Brown Road, Suite 101, Ithaca, New York, USA
| | - Véronique Gouverneur
- University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, UK
| | - Steven H. Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit Street, Boston, USA
- Department of Radiology, Harvard Medical School, 55 Fruit Street, Boston, USA
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, 55 Fruit Street, Boston, USA
- Department of Radiology, Harvard Medical School, 55 Fruit Street, Boston, USA
| |
Collapse
|
47
|
Frese J, Morgenroth A, Mertens ME, Koch S, Rongen L, Vogg ATJ, Zlatopolskiy BD, Neumaier B, Gesche VN, Lammers T, Schmitz-Rode T, Mela P, Jockenhoevel S, Mottaghy FM, Kiessling F. Nondestructive monitoring of tissue-engineered constructs. ACTA ACUST UNITED AC 2015; 59:165-75. [PMID: 24021591 DOI: 10.1515/bmt-2013-0029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 08/13/2013] [Indexed: 11/15/2022]
Abstract
Abstract Tissue engineering as a multidisciplinary field enables the development of living substitutes to replace, maintain, or restore diseased tissue and organs. Since the term was introduced in medicine in 1987, tissue engineering strategies have experienced significant progress. However, up to now, only a few substitutes were able to overcome the gap from bench to bedside and have been successfully approved for clinical use. Substantial donor variability makes it difficult to predict the quality of tissue-engineered constructs. It is essential to collect sufficient data to ensure that poor or immature constructs are not implanted into patients. The fulfillment of certain quality requirements, such as mechanical and structural properties, is crucial for a successful implantation. There is a clear need for new nondestructive and real-time online monitoring and evaluation methods for tissue-engineered constructs, which are applicable on the biomaterial, tissue, cellular, and subcellular levels. This paper reviews current established nondestructive techniques for implant monitoring including biochemical methods and noninvasive imaging.
Collapse
|
48
|
Liang SH, Yokell DL, Normandin MD, Rice PA, Jackson RN, Shoup TM, Brady TJ, El Fakhri G, Collier TL, Vasdev N. First human use of a radiopharmaceutical prepared by continuous-flow microfluidic radiofluorination: proof of concept with the tau imaging agent [18F]T807. Mol Imaging 2015; 13. [PMID: 25248283 DOI: 10.2310/7290.2014.00025] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Despite extensive preclinical imaging with radiotracers developed by continuous-flow microfluidics, a positron emission tomographic (PET) radiopharmaceutical has not been reported for human imaging studies by this technology. The goal of this study was to validate the synthesis of the tau radiopharmaceutical 7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole ([18F]T807) and perform first-in-human PET scanning enabled by microfluidic flow chemistry. [18F]T807 was synthesized by our modified one-step method and adapted to suit a commercial microfluidic flow chemistry module. For this proof of concept, the flow system was integrated to a GE Tracerlab FXFN unit for high-performance liquid chromatography purification and formulation. Three consecutive productions of [18F]T807 were conducted to validate this radiopharmaceutical. Uncorrected radiochemical yields of 17 ± 1% of crude [18F]T807 (≈ 500 mCi, radiochemical purity 95%) were obtained from the microfluidic device. The crude material was then purified, and > 100 mCi of the final product was obtained in an overall uncorrected radiochemical yield of 5 ± 1% (n = 3), relative to starting [18F]fluoride (end of bombardment), with high radiochemical purity (≥ 99%) and high specific activities (6 Ci/μmol) in 100 minutes. A clinical research study was carried out with [18F]T807, representing the first reported human imaging study with a radiopharmaceutical prepared by this technology.
Collapse
|
49
|
Stanek J, Mairinger S, Wanek T, Kuntner C, Müller M, Langer O. Automated radiosynthesis of [(18)F]ciprofloxacin. Appl Radiat Isot 2015; 99:133-7. [PMID: 25752570 DOI: 10.1016/j.apradiso.2015.02.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Revised: 02/18/2015] [Accepted: 02/26/2015] [Indexed: 10/23/2022]
Abstract
We transferred the previously published manual synthesis of [(18)F]ciprofloxacin (decay-corrected RCY: 5.5±1.0%) to an automated synthesis module (TRACERlab(TM) FXFDG, GE Healthcare) and observed a strong decrease in RCY (0.4±0.4%). When replacing the standard 15-mL glassy carbon reactor of the synthesis module with a 3-mL V-shaped borosilicate glass reactor a considerable improvement in RCY was observed. [(18)F]Ciprofloxacin was obtained in a RCY of 2.7±1.4% (n=23) with a specific activity at EOS of 1.4±0.5GBq/µmol in a synthesis time of 160min.
Collapse
Affiliation(s)
- Johann Stanek
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, A-2444 Seibersdorf, Austria; Department of Clinical Pharmacology, Medical University of Vienna, Währiger-Gürtel 18-20, A-1090 Vienna, Austria
| | - Severin Mairinger
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, A-2444 Seibersdorf, Austria
| | - Thomas Wanek
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, A-2444 Seibersdorf, Austria
| | - Claudia Kuntner
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, A-2444 Seibersdorf, Austria
| | - Markus Müller
- Department of Clinical Pharmacology, Medical University of Vienna, Währiger-Gürtel 18-20, A-1090 Vienna, Austria
| | - Oliver Langer
- Health and Environment Department, AIT Austrian Institute of Technology GmbH, A-2444 Seibersdorf, Austria; Department of Clinical Pharmacology, Medical University of Vienna, Währiger-Gürtel 18-20, A-1090 Vienna, Austria.
| |
Collapse
|
50
|
Zheng MQ, Collier L, Bois F, Kelada OJ, Hammond K, Ropchan J, Akula MR, Carlson DJ, Kabalka GW, Huang Y. Synthesis of [(18)F]FMISO in a flow-through microfluidic reactor: Development and clinical application. Nucl Med Biol 2015; 42:578-84. [PMID: 25779036 DOI: 10.1016/j.nucmedbio.2015.01.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Revised: 01/26/2015] [Accepted: 01/27/2015] [Indexed: 01/16/2023]
Abstract
INTRODUCTION The PET radiotracer [(18)F]FMISO has been used in the clinic to image hypoxia in tumors. The aim of the present study was to optimize the radiochemical parameters for the preparation of [(18)F]FMISO using a microfluidic reaction system. The main parameters evaluated were (1) precursor concentration, (2) reaction temperature, and (3) flow rate through the microfluidic reactor. Optimized conditions were then applied to the batch production of [(18)F]FMISO for clinical research use. METHODS For the determination of optimal reaction conditions within a flow-through microreactor synthesizer, 5-400 μL the precursor and dried [(18)F]fluoride solutions in acetonitrile were simultaneously pushed through the temperature-controlled reactor (60-180 °C) with defined flow rates (20-120 μL/min). Radiochemical incorporation yields to form the intermediate species were determined using radio-TLC. Hydrolysis to remove the protecting group was performed following standard vial chemistry to afford [(18)F]FMISO. RESULTS Optimum reaction parameters for the microfluidic set-up were determined as follows: 4 mg/mL of precursor, 170 °C, and 100 μL/min pump rate per reactant (200 μL/min reaction overall flow rate) to prepare the radiolabeled intermediate. The optimum hydrolysis condition was determined to be 2N HCl for 5 min at 100 °C. Large-scale batch production using the optimized conditions gave the final, ready for human injection [(18)F]FMISO product in 28.4 ± 3.0% radiochemical yield, specific activity of 119 ± 26 GBq/μmol, and >99% radiochemical and chemical purity at the end of synthesis (n = 4). CONCLUSION By using the NanoTek microfluidic synthesis system, [(18)F]FMISO was successfully prepared with good specific activity and high radiochemical purity for human use. The product generated from large-scale batch production using flow chemistry is currently being used in clinical research.
Collapse
Affiliation(s)
- Ming-Qiang Zheng
- PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, United States.
| | - Lee Collier
- Advion, Ithaca, NY, United States; Department of Radiology, University of Tennessee, Knoxville, TN, United States.
| | - Frederic Bois
- PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, United States
| | - Olivia J Kelada
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States
| | | | - Jim Ropchan
- PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, United States
| | - Murthy R Akula
- Department of Radiology, University of Tennessee, Knoxville, TN, United States
| | - David J Carlson
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States
| | - George W Kabalka
- Department of Chemistry, University of Tennessee, Knoxville, TN, United States; Department of Radiology, University of Tennessee, Knoxville, TN, United States
| | - Yiyun Huang
- PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, United States
| |
Collapse
|